Want to see SE:HEART full AI Analyst Report?
HEART Stock Chart & Stats
kr25.80
kr0.30(2.04%)
At close: 4:00 PM EST
kr25.80
kr0.30(2.04%)
Day’s Range― - ―
52-Week Rangekr12.90 - kr29.89
Previous CloseN/A
Volume1.18K
Average Volume (3M)4.36K
Market Cap
kr150.84M
Enterprise Valuekr151.30
Total Cash (Recent Filing)kr27.94M
Total Debt (Recent Filing)kr5.40M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume5,954
30 Day Avg. Volume4,362
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Bulls Say, Bears Say
Bulls Say
Artificial-heart Product OpportunityThe Realheart TAH targets patients with severe heart failure and is intended as an alternative to transplantation or other mechanical support. If validated and approved, this focused product could address a serious clinical need and support a specialized medtech market position.
Low Financial LeverageLow debt relative to equity reduces fixed financial obligations and provides more flexibility than a highly leveraged balance sheet. This can help the company direct available funding toward development, regulatory work, and commercialization rather than substantial debt servicing.
Focused Development PlatformThe company has a defined development pathway spanning product research, validation, regulatory preparation, and commercialization. That focused operating model can concentrate limited resources on advancing one core artificial-heart platform through the milestones needed for future market access.
Bears Say
Pre-revenue Business ModelThe company has not yet demonstrated a consistent commercial revenue stream, leaving its business model dependent on future product progress and market authorization. Until sales begin at meaningful scale, operating costs are unlikely to be funded by customer demand.
Persistent Operating LossesDeep and volatile losses indicate that ongoing R&D and operating expenditure have not yet produced stable commercial earnings or operating leverage. Continued losses could extend the period before the business becomes self-sustaining and increase reliance on external financing.
Sustained Cash Burn And Dilution RiskNegative operating and free cash flow show that the company is not self-funding its activities, while the declining equity base highlights the financial impact of ongoing losses. Continued funding needs may constrain execution and increase dilution risk if equity financing is required.
HEART FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was kr12.90 and its highest was kr29.89 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is kr150.84M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is Nov 12, 2026 which is in 42 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Scandinavian Real Heart AB released its earnings results on Aug 26, 2026. The company reported -kr2.82 earnings per share for the quarter.
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 8,497,797 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Scandinavian Real Heart AB reported an EPS of -kr2.82 in its last earnings report. Following the earnings report the stock price went up 1.872%.
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in SE:HEART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to address severe cases of heart failure. Beyond this central project, their product portfolio also encompasses medical solutions such as the RealVAD, PulsePump, and Sternal Prosthesis. The firm operates from its base in Västerås, Sweden.